Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ).
IRLAB Therapeutics has appointed Gustaf Albèrt as the new Chief Financial Officer, effective November 17, 2025. Albèrt brings extensive experience from senior financial roles in the biotech sector, including positions at Isofol Medical and Aqilion. His appointment is expected to bolster IRLAB’s management team as the company continues its focus on value creation and advancing its pipeline of Parkinson’s disease treatments.
The most recent analyst rating on ($SE:IRLAB.A) stock is a Sell with a SEK3.00 price target. To see the full list of analyst forecasts on IRLAB Therapeutics AB Class A stock, see the SE:IRLAB.A Stock Forecast page.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing innovative treatments for Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research, the company is advancing a portfolio of treatments through various clinical phases, including Mesdopetam for levodopa-induced dyskinesias and Pirepemat for reducing fall frequency in Parkinson’s patients. IRLAB utilizes its proprietary Integrative Screening Process (ISP) for drug discovery and is listed on Nasdaq Stockholm.
Average Trading Volume: 217,207
Technical Sentiment Signal: Sell
Current Market Cap: SEK238.3M
See more insights into IRLAB.A stock on TipRanks’ Stock Analysis page.